Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지

Current use of growth hormone in children

성장호르몬 치료의 최신 지견

  • Shin, Choong Ho (Department of Pediatrics, College of Medicine, Seoul National University)
  • 신충호 (서울대학교 의과대학 소아과학교실)
  • Received : 2006.06.10
  • Accepted : 2006.06.15
  • Published : 2006.07.15
Download PDF
⟨ Previous Next ⟩

Abstract

Since the advent of growth hormone(GH), children with a wide variety of growth disorders have received GH treatment. In GH deficiency(GHD), Turner syndrome, chronic renal failure, children born small for gestational age, Prader-Willi syndrome, and idiopathic short stature, the therapeutic effects and safety profile of GH are reviewed. GH therapy has been clearly shown to improve height velocity and final adult height in a variety of pediatric conditions in which growth is compromised irrespective of GHD. Early initiation and individualization of GH treatment has the potential to normalize childhood growth. The supra-physiological doses of GH have been shown to increase height velocity during childhood and final height in non-GHD conditions. Adverse events during GH therapy are uncommon and often not drug related. However continued surveillance into adult life is crucial, especially in children receiving supra-physiological doses or whose underlying condition increases their risk of adverse effects.

Keywords

References

  1. Wilson TA, Rose SR, Cohen P, Rogol AD, Backeljauw P, Brown R, et al. The Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee. Update of guidelines for the use of growth hormone in children : the Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee. J Pediatr 2003;143:415-21 https://doi.org/10.1067/S0022-3476(03)00246-4
  2. Gharib H, Cook DM, Saenger PH, Bengtsson BA, Feld S, Nippoldt TB, et al. American Association of Clinical Endocrinologists Growth Hormone Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in adults and children--2003 update. Endocr Pract 2003;9:64-76 https://doi.org/10.4158/EP.9.1.64
  3. Cutfield W, Lindberg A, Albertsson-Wikland K, Chatelain P, Ranke MB, Wilton P. Final height in idiopathic growth hormone deficiency : the KIGS experience. KIGS International Board. Acta Paediatr Suppl 1999;88:72-5
  4. Gleeson HK, Shalet SM. The impact of cancer therapy on the endocrine system in survivors of childhood brain tumours. Endocr Relat Cancer 2004;11:589-602 https://doi.org/10.1677/erc.1.00779
  5. Harris M, Hofman PL, Cutfield WS. Growth hormone treatment in children : review of safety and efficacy. Paediatr Drugs 2004;6:93-106 https://doi.org/10.2165/00148581-200406020-00003
  6. Shin JH, Ko CW, Kim DH, Kim JD, Kim HS, Kim HS, et al. Spontaneous growth in Korean patients with Turner syndrome. J Korean Soc Pediatr Endocrinol 1998;3:1-6
  7. Haeusler G, Schmitt K, Blumel P, Plochl E, Waldhor T, Frisch H. Growth hormone in combination with anabolic steroids in patients with Turner syndrome : effect on bone maturation and final height. Acta Paediatr 1996;85:1408-14
  8. Saenger P, Wikland KA, Conway GS, Davenport M, Gravholt CH, Hintz R, et al. Fifth International Symposium on Turner Syndrome. Recommendations for the diagnosis and management of Turner syndrome. J Clin Endocrinol Metab 2001;86:3061-9 https://doi.org/10.1210/jc.86.7.3061
  9. Rosenfield RL, Devine N, Hunold JJ, Mauras N, Moshang T Jr, Root AW. Salutary effects of combining early very low-dose systemic estradiol with growth hormone therapy in girls with Turner syndrome. J Clin Endocrinol Metab 2005;90:6424-30 https://doi.org/10.1210/jc.2005-1081
  10. Rizzoni G, Broyer M, Brunner FP, Brynger H, Challah S, Kramer P, et al. Combined report on regular dialysis and transplantation of children in Europe, XIII, 1983. Proc Eur Dial Transplant Assoc Eur Ren Assoc 1985;21:66-95
  11. Rabkin R, Sun DF, Chen Y, Tan J, Schaefer F. Growth hormone resistance in uremia, a role for impaired JAK/ STAT signaling. Pediatr Nephrol 2005;20:313-8 https://doi.org/10.1007/s00467-004-1713-8
  12. van Diemen-Steenvoorde R, Donckerwolcke RA, Brackel H, Wolff ED, de Jong MC. Growth and sexual maturation in children after kidney transplantation. J Pediatr 1987;110: 351-6
  13. Vimalachandra D, Craig JC, Cowell CT, Knight JF. Growth hormone treatment in children with chronic renal failure : a meta-analysis of randomized controlled trials. J Pediatr 2001;139:560-7 https://doi.org/10.1067/mpd.2001.117582
  14. Kari JA, Rees L. Growth hormone for children with chronic renal failure and on dialysis. Pediatr Nephrol 2005;20: 618-21 https://doi.org/10.1007/s00467-004-1801-9
  15. Haffner D, Schaefer F, Nissel R, Wuhl E, Tonshoff B, Mehls O. Effect of growth hormone treatment on the adult height of children with chronic renal failure. German Study Group for Growth Hormone Treatment in Chronic Renal Failure. N Engl J Med 2000;343:923-30 https://doi.org/10.1056/NEJM200009283431304
  16. Fine RN. Growth post renal-transplantation in children : lessons from the North American Pediatric Renal Transplant Cooperative Study(NAPRTCS). Pediatr Transplant 1997;1:85-9
  17. Fine RN, Ho M, Tejani A. North American Pediatric Renal Trasplant Cooperative Study(NAPRTCS). The contribution of renal transplantation to final adult height : a report of the North American Pediatric Renal Transplant Cooperative Study(NAPRTCS). Pediatr Nephrol 2001;16:951-6 https://doi.org/10.1007/s004670100002
  18. Fine RN, Sullivan EK, Kuntze J, Blethen S, Kohaut E. The impact of recombinant human growth hormone treatment during chronic renal insufficiency on renal transplant recipients. J Pediatr 2000;136:376-82 https://doi.org/10.1067/mpd.2000.103850
  19. Mehls O, Wilton P, Lilien M, Berg U, Broyer M, Rizzoni G, et al. Does growth hormone treatment affect the risk of post-transplant renal cancer? Pediatr Nephrol 2002;17:984-9 https://doi.org/10.1007/s00467-002-0962-7
  20. Albertsson-Wikland K, Karlberg J. Natural growth in children born small for gestational age with and without catch-up growth. Acta Paediatr Suppl 1994;399:64-70
  21. Lee PA, Chernausek SD, Hokken-Koelega AC, Czernichow P. International Small for Gestational Age Advisory Board. International Small for Gestational Age Advisory Board consensus development conference statement : management of short children born small for gestational age, April 24- October 1, 2001. Pediatrics 2003;111:1253-61 https://doi.org/10.1542/peds.111.6.1253
  22. Tanner JM, Lejarraga H, Cameron N. The natural history of the Silver-Russell syndrome : a longitudinal study of thirty-nine cases. Pediatr Res 1975;9:611-23 https://doi.org/10.1203/00006450-197508000-00001
  23. Hokken-Koelega AC. Timing of puberty and fetal growth. Best Pract Res Clin Endocrinol Metab 2002;16:65-71 https://doi.org/10.1053/beem.2002.0181
  24. Lazar L, Pollak U, Kalter-Leibovici O, Pertzelan A, Phillip M. Pubertal course of persistently short children born small for gestational age(SGA) compared with idiopathic short children born appropriate for gestational age(AGA). Eur J Endocrinol 2003;149:425-32 https://doi.org/10.1530/eje.0.1490425
  25. Johnston LB, Savage MO. Should recombinant human growth hormone therapy be used in short small for gestational age children? Arch Dis Child 2004;89:740-4 https://doi.org/10.1136/adc.2003.034785
  26. Van Dijk M, Mulder P, Houdijk M, Mulder J, Noordam K, Odink RJ, et al. High serum levels of growth hormone(GH) and insulin-like growth factor-I(IGF-I) during high-dose GH treatment in short children born small for gestational age. J Clin Endocrinol Metab 2006;91:1390-6 https://doi.org/10.1210/jc.2005-1663
  27. Van Pareren Y, Mulder P, Houdijk M, Jansen M, Reeser M, Hokken-Koelega A. Adult height after long-term, continuous growth hormone(GH) treatment in short children born small for gestational age : results of a randomized, double-blind, dose-response GH trial. J Clin Endocrinol Metab 2003;88:3584-90 https://doi.org/10.1210/jc.2002-021172
  28. Ong K, Beardsall K, de Zegher F. Growth hormone therapy in short children born small for gestational age. Early Hum Dev 2005;81:973-80 https://doi.org/10.1016/j.earlhumdev.2005.10.010
  29. de Zegher F, Hokken-Koelega A. Growth hormone therapy for children born small for gestational age : height gain is less dose dependent over the long term than over the short term. Pediatrics 2005;115:e458-62 https://doi.org/10.1542/peds.2004-1934
  30. Boonstra V, van Pareren Y, Mulder P, Hokken-Koelega A. Puberty in growth hormone-treated children born small for gestational age(SGA). J Clin Endocrinol Metab 2003;88: 5753-8 https://doi.org/10.1210/jc.2003-030512
  31. Gubitosi-Klug RA, Cuttler L. Idiopathic short stature. Endocrinol Metab Clin North Am 2005;34:565-80 https://doi.org/10.1016/j.ecl.2005.04.003
  32. Kemp SF, Kuntze J, Attie KM, Maneatis T, Butler S, Frane J, et al. Efficacy and safety results of long-term growth hormone treatment of idiopathic short stature. J Clin Endocrinol Metab 2005;90:5247-53 https://doi.org/10.1210/jc.2004-2513
  33. Finkelstein BS, Imperiale TF, Speroff T, Marrero U, Radcliffe DJ, Cuttler L. Effect of growth hormone therapy on height in children with idiopathic short stature : a metaanalysis. Arch Pediatr Adolesc Med 2002;156:230-40 https://doi.org/10.1001/archpedi.156.3.230
  34. Wit JM, Rekers-Mombarg LT, Cutler GB, Crowe B, Beck TJ, Roberts K, et al. Growth hormone(GH) treatment to final height in children with idiopathic short stature : evidence for a dose effect. J Pediatr 2005;146:45-53 https://doi.org/10.1016/j.jpeds.2004.08.055
  35. Freemark M. Editorial : Growth hormone treatment of 'idiopathic short stature' : not so fast. J Clin Endocrinol Metab 2004;89:3138-9 https://doi.org/10.1210/jc.2004-0671
  36. Kemp SF, Kuntze J, Attie KM, Maneatis T, Butler S, Frane J, et al. Efficacy and safety results of long-term growth hormone treatment of idiopathic short stature. J Clin Endocrinol Metab 2005;90:5247-53 https://doi.org/10.1210/jc.2004-2513
  37. Yanovski JA, Rose SR, Municchi G, Pescovitz OH, Hill SC, Cassorla FG, et al. Treatment with a luteinizing hormonereleasing hormone agonist in adolescents with short stature. N Engl J Med 2003;348:908-17 https://doi.org/10.1056/NEJMoa013555
  38. Lindgren AC, Ritzen EM. Five years of growth hormone treatment in children with Prader-Willi syndrome. Swedish National Growth Hormone Advisory Group. Acta Paediatr Suppl 1999;88:109-11 https://doi.org/10.1111/j.1651-2227.1999.tb14416.x
  39. Carrel AL, Myers SE, Whitman BY, Allen DB. Benefits of long-term GH therapy in Prader-Willi syndrome : a 4-year study. J Clin Endocrinol Metab 2002;87:1581-5 https://doi.org/10.1210/jc.87.4.1581
  40. Wilson SS, Cotterill AM, Harris MA. Growth hormone and respiratory compromise in Prader-Willi syndrome. Arch Dis Child 2006;91:349-50 https://doi.org/10.1136/adc.2005.086090
  41. Eiholzer U. Deaths in children with Prader-Willi syndrome. A contribution to the debate about the safety of growth hormone treatment in children with PWS. Horm Res 2005; 63:33-9 https://doi.org/10.1159/000082745
  42. Sklar CA, Mertens AC, Mitby P, Occhiogrosso G, Qin J, Heller G, et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone : a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2002;87:3136-41 https://doi.org/10.1210/jc.87.7.3136